JP2003529370A5 - - Google Patents

Info

Publication number

JP2003529370A5

JP2003529370A5 JP2001572983A JP2001572983A JP2003529370A5 JP 2003529370 A5 JP2003529370 A5 JP 2003529370A5 JP 2001572983 A JP2001572983 A JP 2001572983A JP 2001572983 A JP2001572983 A JP 2001572983A JP 2003529370 A5 JP2003529370 A5 JP 2003529370A5

Authority

JP

Japan

Prior art keywords

antibody

antibody fragment

tumor

fragment

angiogenesis

Prior art date

2001-03-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 25
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 25
• 206010028980 Neoplasm Diseases 0.000 description 9
• 230000033115 angiogenesis Effects 0.000 description 7
• 102000008790 VE-cadherin Human genes 0.000 description 6
• 108010018828 cadherin 5 Proteins 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
• 239000008194 pharmaceutical composition Substances 0.000 description 5
• 201000010099 disease Diseases 0.000 description 4
• 239000000203 mixture Substances 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 3
• 125000003275 alpha amino acid group Chemical group 0.000 description 3
• 230000000694 effects Effects 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 238000000034 method Methods 0.000 description 3
• 108020004707 nucleic acids Proteins 0.000 description 3
• 102000039446 nucleic acids Human genes 0.000 description 3
• 150000007523 nucleic acids Chemical class 0.000 description 3
• 239000002773 nucleotide Substances 0.000 description 3
• 125000003729 nucleotide group Chemical group 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 210000005166 vasculature Anatomy 0.000 description 3
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 210000004027 cell Anatomy 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 201000001256 adenosarcoma Diseases 0.000 description 1
• 210000002867 adherens junction Anatomy 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1